The long-term outcomes of systemic vasculitis

Nephrology Dialysis Transplantation

Volumn 30, Issue , 2015, Pages i60-i66

  Westman, Kerstin ^a   Flossmann, Oliver ^b   Gregorini, Gina ^c  

^a LUND UNIVERSITY   (Sweden)

^b ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^c SPEDALI CIVILI   (Italy)

Author keywords

cardiovascular disease; malignancy; patient survival; relapse; renal outcomes

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; SYNAPSIN II;

ANCA ASSOCIATED VASCULITIS; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DRUG PULSE THERAPY; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RENAL REPLACEMENT THERAPY; REVIEW; SKIN CANCER; SURVIVAL TIME; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS; MORTALITY; PROGNOSIS; SURVIVAL RATE; SYSTEMIC VASCULITIS;

HUMANS; PROGNOSIS; SURVIVAL RATE; SYSTEMIC VASCULITIS;

EID: 84926635622     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu392     Document Type: Review

References (53)

1. Fauci AS, Wolff SM. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine 1973; 52: 535-561
2. Frohnert P, Sheps S. Long-term follow-up study of periarteritis nodosa. Am J Med 1967; 43: 8-14
3. Fauci AS, Haynes BF, Katz P et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85
4. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-498
5. Flossmann O, Berden A, de Groot K et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70: 488-494
6. Andrassy K, Erb A, Koderisch J et al. Wegener's granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. Clin Nephrol 1991; 35: 139-147
7. Franssen CF, Gans RO, Arends B et al. Differences between anti-myeloperoxidase-and anti-proteinase 3-associated renal disease. Kidney Int 1995; 47: 193-199
8. Matteson EL, Gold KN, Bloch DA et al. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. Am J Med 1996; 101: 129-134
9. Hogan SL, Nachman PH, Wilkman AS et al. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 23-32
10. Brijker F, Magee CC, Tervaert JW et al. Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies. Clin Nephrol 1999; 52: 344-351
11. Reinhold-Keller E, Beuge N, Latza U et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-1032
12. Aasarod K, Iversen BM, Hammerstrom J et al. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000; 15: 611-618
13. Cohen B, Clark W. Pauci-immune renal vasculitis: natural history, prognostic factors, and impact of therapy. Am J Kidney Dis 2000; 36: 914-924
14. Mahr A, Girard T, Agher R et al. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. Rheumatology 2001; 40: 492-498
15. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology 2002; 41: 572-581
16. Booth AD, Almond MK, Burns A et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41: 776-784
17. Weidner S, Geuss S, Hafezi-Rachti S et al. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004; 19: 1403-1411
18. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century-A disease of older patients. Rheumatology 2005; 44: 495-501
19. Rihova Z, Jancova E, Merta M et al. Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement. Kidney Blood Press Res 2005; 28: 144-152
20. Westman KW, Selga D, Isberg PE et al. High proteinase 3-anti-neutrophil cytoplasmic antibody (ANCA) level measured by the capture enzyme-linked immunosorbent assay method is associated with decreased patient survival in ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 2003; 14: 2926-2933
21. Bligny D, Mahr A, Toumelin PL et al. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 2004; 51: 83-91
22. Holle JU, Gross WL, Latza U et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011; 63: 257-266
23. Nakaya I, Yahata M, Takahashi S et al. Long-term outcome and efficacy of cyclophosphamide therapy in Japanese patients with ANCA-associated microscopic polyangiitis: a retrospective study. Intern Med 2013; 52: 2503-2509
24. Slot MC, Tervaert JW, Franssen CF et al. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003; 63: 670-677
25. Westman KW, Bygren PG, Olsson H et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998; 9: 842-852
26. Hogan SL, Falk RJ, Chin H et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vas-culitis. Ann Intern Med 2005; 143: 621-631
27. Hruskova Z, Casian AL, Konopasek P et al. Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study. Scand J Rheumatol 2013; 42: 211-214
28. Gordon M, Luqmani RA, Adu D et al. Relapses in patients with a systemic vasculitis. QJM 1993; 86: 779-789
29. Walsh M, Flossmann O, Berden A et al. Risk factors for relapse of antineu-trophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 542-548
30. Pagnoux C, Hogan SL, Chin H et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vas-culitis: comparison of two independent cohorts. Arthritis Rheum 2008; 58: 2908-2918
31. Slot MC, Tervaert JW, Boomsma MM et al. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004; 51: 269-273
32. Harper L, Morgan MD, Walsh M et al. Pulse versus daily oral cyclophos-phamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71: 955-960
33. Faurschou M, Westman K, Rasmussen N et al. Long-term outcome of a clinical trial comparing methotrexate to cyclophosphamide for remission induction of early systemic ANCA-associated vasculitis. Arthritis Rheum 2012; 64: 3472-3477
34. Guillevin L, Cordier J-F, Lhote F et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oal cyclophosphamide in the treatment of genralized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-2198
35. Walsh M, Merkel PA, Mahr A et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res 2010; 62: 1166-1173
36. Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: 2180-2188
37. de Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 2013; 8: 1709-1717
38. Hilhorst M, Wilde B, van Paassen P et al. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant 2013; 28: 373-379
39. Marco H, Mirapeix E, Arcos E et al. Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation. Clin Transplant 2013; 27: 338-347
40. Nachman PH, Segelmark M, Westman K et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis. Kidney Int 1999; 56: 1544-1550
41. Tang W, Bose B, McDonald SP et al. The outcomes of patients with ESRD and ANCA-associated vasculitis in Australia and New Zealand. Clin J Am Soc Nephrol 2013; 8: 773-780
42. Faurschou M, Mellemkjaer L, Sorensen IJ et al. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 2009; 60: 1187-1192
43. Morgan MD, Turnbull J, Selamet U et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vas-culitides: a matched-pair cohort study. Arthritis Rheum 2009; 60: 3493-3500
44. Suppiah R, Judge A, Batra R et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res 2011; 63: 588-596
45. Hornum M, Lindahl JP, von Zur-Mühlen B et al. Diagnosis, management and treatment of glucometabolic disorders emerging after kidney transplantation. Transplant Int 2013; 26: 1049-1060
46. Hoffman GS, Leavitt RY, Kerr GS et al. The treatment of Wegeners granu-lomatosis with glucocorticoids and methotrexate. Athritis Rheum 1992; 35: 6112-6128
47. Faurschou M, Sorensen IJ, Mellemkjaer L et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008; 35: 100-105
48. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002; 100: 82-85
49. Silva F, Seo P, Schroeder DR et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum 2011; 63: 2495-2503
50. Morath C, Mueller M, Goldschmidt H et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004; 15: 1582-1588
51. Talar-Williams C, Hijazi YM, Walther MC et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granuloma-tosis. Ann Intern Med 1996; 124: 477-484
52. Le Guenno G, Mahr A, Pagnoux C et al. Incidence and predictors of uro-toxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 2011; 63: 1435-1445
53. Heijl C, Harper L, Flossmann O et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 2011; 70: 1415-1421